Literature DB >> 23995377

Current trends in immunosuppression following organ transplantation in children.

Siah Kim1, Angela C Webster, Jonathan C Craig.   

Abstract

PURPOSE OF REVIEW: To highlight the current trends in immunosuppression and their application to paediatric transplantation informed by the systematic reviews and randomized controlled trials: new induction agents, steroid avoidance, calcineurin minimization and desensitization protocols. RECENT
FINDINGS: Newer induction agents, belatacept and alemtuzumab, are associated with serious side-effects, and interleukin-2 receptor antagonists remain the preferred agents in children. Steroid-free regimens may improve growth and, compared with steroid-containing regimens, have similar short to medium term graft survival, although long-term outcomes are uncertain. Mammalian target of rapamycin inhibitors, sirolimus and everolimus, when used in recipients as primary immunosuppression to avoid calcineurin exposure, results in poorer graft survival. Although desensitization is being performed more frequently, the relative benefits and harms of regimens used are uncertain.
SUMMARY: There is growing evidence for the use of steroid-free immunosuppression regimens in children to maximize growth. Further trials with a focus on long-term graft survival are needed to establish the role of desensitization protocols in organ transplantation in children.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23995377     DOI: 10.1097/MOT.0b013e3283651b35

Source DB:  PubMed          Journal:  Curr Opin Organ Transplant        ISSN: 1087-2418            Impact factor:   2.640


  2 in total

Review 1.  Challenges in pediatric renal transplantation.

Authors:  Licia Peruzzi; Alessandro Amore; Rosanna Coppo
Journal:  World J Transplant       Date:  2014-12-24

Review 2.  Current management issues of immediate postoperative care in pediatric kidney transplantation.

Authors:  Fabio Cesar Miranda Torricelli; Andreia Watanabe; Elias David-Neto; William Carlos Nahas
Journal:  Clinics (Sao Paulo)       Date:  2014       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.